We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
India flouts patent for blockbuster biologic.
- Authors
Jayaraman, Killugudi
- Abstract
The article offers information about Pegasys which is marketed by the multinational Roche of Basel, for use with ribavirin in treatment of hepatitis C virus (HCV). It informs that the Intellectual Property Appellate Board (IPAB) has withdrew a patent granted to Pegasys as drug is similar to the process by which polyethylene glycol (PEG) is added to Interferons alpha2 and it has high cost. It also discusses about several other pharma products which are facing challenges on similar ground.
- Subjects
HEPATITIS C virus; DRUG prices; F. Hoffmann-La Roche Ltd.; POLYETHYLENE glycol; PATENTS; INTELLECTUAL property; RIBAVIRIN
- Publication
Nature Biotechnology, 2013, Vol 31, Issue 1, p9
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0113-9